Clinical commissioning work programmes

Last updated: September 2019

The tables below cover the clinical commissioning policies currently in the process of being prepared for publication, covering the policy work programmes for clinical commissioning policies, specialised commissioning service specifications, and commissioning through evaluation (CtE).

Abbreviations: NPoC=National Programme of Care; IYSD=in-year service development; CSP=Clinical Support Programme; HSS=Highly Specialised Services; CPAG=Clinical Priorities Advisory Group; CRG=Clinical Reference Group; HCC=hepatocellular carcinoma

Clinical commissioning policies

wdt_ID ID Therapy/procedure Indication NPoC Product Status Target
1 1606 Bendamustine Relapsed chronic lymphatic leukaemia Cancer Policy Impact assessment in progress TBC
2 1622 Lung volume reduction Severe emphysema Internal Medicine Policy Awaiting prioritisation annoucement 2019/20 IYSD
4 1691 Temozolomide Grade 3 anaplastic astrocytoma of the brain Cancer Policy Awaiting prioritisation annoucement 2020/21 Q1/Q2
5 1693 Long term left ventricular assist device therapy Advanced heart failure (all ages) Internal Medicine Policy Awaiting publication 2019/20 IYSD
6 1709 Recombinant manufactured von Willebrand factor von Willebrand disease Blood & Infection NICE CSP Awaiting prioritisation annoucement 2019/20 Q3/Q4
9 1716 Human coagulation factor X Hereditary factor X deficiency (all ages) Blood & Infection Policy Awaiting prioritisation annoucement 2019/20 Q3/Q4
10 1745 Telotristat Carcinoid syndrome Internal Medicine NICE CSP Awaiting publication 2019/20 IYSD
12 1748 Addition of rituximab to standard chemotherapy of first line treatment Adult patients with CD20 positive B-cell precursor acute lymphoblastic leukaemia Cancer Policy Awaiting CPAG 2019/20 IYSD
14 1783 Proton beam radiotherapy Curative childhood cancers Cancer Policy Awaiting publication 2019/20 IYSD
15 1787 Proton neam therapy Cancer of the breast Cancer Policy Impact assessment in progress TBC
ID Therapy/procedure Indication NPoC Product Status Target

Specialised Commissioning service specifications

wdt_ID ID Title Status Target HSS
1 1632 Neurosciences—neuropsychiatry Awaiting CPAG 2019/20 Q2 No
2 1640 Cystinosis service Specification in development 2019/20 Q1/Q2 Yes
5 1645 Specialised liver services including liver cancer Specification in development 2019/20 IYSD No
6 1646 Specialised pancreatic services including pancreatic cancer Specification in development 2019/20 IYSD No
7 1647 Clinical medical genetics Specification in development 2019/20 IYSD No
8 1649 Specialised gynaecology surgery for complex urinary incontinence and prolapse Awaiting publication 2019/20 IYSD No
9 1652 Abnormally invasive placenta Awaiting publication 2019/20 IYSD No
10 1653 Vesico vaginal fistulae service Awaiting publication 2019/20 IYSD No
12 1656 Specialised endocrinology Specification in development 2019/20 IYSD No
13 1662 Inherited White Matter Disorders Service (HSS) Impact Assessment 2019/20 Q1/Q2 Yes
ID Title Status Target HSS

Commissioning through evaluation

wdt_ID ID Title CRG NPoC Decision Status Notes
1 C0009 Rituximab for idiopathic membraneous nephropathy A06. Renal services Internal medicine Supported to proceed to implementation Recruitment; in progress The scheme is in recruitment phase and plans to recruit 180 patients, by the end of May, 93 patients from 25 sites had been recruited. The evaluation report is expected in November 2021.
2 C0016 Stereotactic ablative radiotherapy (SABR) B01. Radiotherapy Cancer Supported to proceed to implementation Recruitment; in progress The Clinical Panel decided to await the evaluative commissioning reports and revised evidence reviews due in July 2019. The reports for HCC will need to be considered in draft form as they had been planned for completion in August.
ID Title CRG NPoC Decision Status Notes

Contains public sector information licensed under the Open Government License v3.0.

The original version of these tables can be found on the NHS England website.